Psychiatr. praxi. 2022;23(3):144-149 | DOI: 10.36290/psy.2022.029

Some of the less frequent side effects of antipsychotics

MUDr. Michaela Mayerová, Ph.D.1, prof. MUDr. Bc. Libor Ustohal, Ph.D.1, 2
1 Psychiatrická klinika, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity, Brno
2 Ústav farmakologie a toxikologie, Farmaceutická fakulta Masarykovy univerzity, Brno

The article summarizes some of the side effects of antipsychotics that are not common in everyday clinical practice, although the patients were treated by commonly used antipsychotics. The information from literature is supplemented by cases of the patients treated by us. We focused on thromboses and anticholinergic deliria, but some other side effects are mentioned as well. The causes, circumstances of initiation and clinical management of these side effects are disscused.

Keywords: side effects, thromboses, anticholinergic deliria, antipsychotics.

Accepted: October 11, 2022; Published: October 25, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mayerová M, Ustohal L. Some of the less frequent side effects of antipsychotics. Psychiatr. praxi. 2022;23(3):144-149. doi: 10.36290/psy.2022.029.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Masopust J, Malý R, Urban A, Hosák L, Čermáková E. Antipsychotic drugs as a risk factor for venous thromboembolism. International Journal of Psychiatry in Clinical Practice. 2007;11(3):246-249. doi:10.1080/13651500601017357. Go to original source... Go to PubMed...
    2. Di X, Chen M, Shen S, Cui X. Antipsychotic use and Risk of Venous Thromboembolism: A Meta-Analysis. Psychiatry Research. 2021;296. doi:10.1016/j.psychres.2020.113691. Go to original source... Go to PubMed...
    3. Liu Y, Xu J, Fang K, et al. Current antipsychotic agent use and risk of venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis of observational studies. Therapeutic Adavances in Psychopharmacology. 2021;11:2045125320982720. doi:10.1177/2045125320982720. Go to original source... Go to PubMed...
    4. Serhat Tunç, Hamit Serdar Başbuğ. An unusual complication of a long-acting injectable antipsychotic: deep venous thrombosis caused by olanzapine pamoate. Psychiatry and Clinical Psychopharmacology. 2018;28(2):211-214. doi:10.1080/24750573.2017.1406036. Go to original source...
    5. Hägg S, Spigset O, Söderström TG. Association of venous thromboembolism and clozapine. Lancet (London, England). 2000;355(9210):1155-1156. doi:10.1016/S0140-6736(00)02066-3. Go to original source... Go to PubMed...
    6. Arghavan Fariborzifar, Forouzan Elyasi, Marziyeh Azizi. Sudden Increase of Antipsychotics and Induction of Deep Vein Thrombosis. Case Reports in Clinical Practice. 2020;5(1). doi:10.18502/crcp.v5i1.3610. Go to original source...
    7. Ogłodek EA, Just MJ, Grzesińska AD, Araszkiewicz A, Szromek AR. The impact of antipsychotics as a risk factor for thromboembolism. Pharmacological Reports. 2018;70(3):533-539. doi:10.1016/j.pharep.2017.12.003. Go to original source... Go to PubMed...
    8. Masopust J, Kopeček M, Protopopová D. Sledování tělesného zdraví u pacientů se závažnými neorganickými duševními poruchami (psychózy, bipolární porucha, depresivní porucha). Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. 2020. https://postupy-pece.psychiatrie.cz/obecna-psychiatrie/sledovani-telesneho-zdravi.
    9. Lauretani F, Ceda GP, Maggio M et al. Capturing sideeffect of medication to identify persons at risk of delirium. Aging Clinical and Experimental Research. 2010;22 (5-6): 456-8. Go to original source... Go to PubMed...
    10. Hiemke C, Baumann P, Bergemann N, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry. 2011;44(6):195-235. Go to original source... Go to PubMed...
    11. de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Progress In Neuro-Psychopharmacology & Biological Psychiatry. 2003;27(6):1059-1063. Go to original source... Go to PubMed...
    12. Leponex. Souhrn údajů o přípravku, datum revize textu 19.7.2022. [Internet]. http://www.sukl.cz/modules/medication/detail.php?code=0235103&tab=texts.
    13. Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opinion on Drug Safety. 2011;10(5):751-765. Go to original source... Go to PubMed...
    14. Nishtala PS, Salahudeen MS, Hilmer SN. Anticholinergics: theoretical and clinical overview. Expert Opinion on Drug Safety. 2016;15(6):753-768. Go to original source... Go to PubMed...
    15. Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age and Ageing. 2011; 40(1):23-29. Go to original source... Go to PubMed...
    16. Dawson AH; Buckley NA. Pharmacological management of anticholinergic delirium-theory, evidence and practice. British Journal of Clinical Pharmacology. 2016; 81(3):516-524. Go to original source... Go to PubMed...
    17. Spring JD, Goldstein BN, Buster M, Mahmoud AA, Hamm B. Physostigmine for Facilitation of Care in Clozapine-Associated Anticholinergic Delirium. Journal of clinical psychopharmacology. 2022;42(3):329-331. doi:10.1097/JCP.0000000000001533. Go to original source... Go to PubMed...
    18. Blackman G, Oloyede E. Clozapine discontinuation withdrawal symptoms in schizophrenia. Therapeutic Advances in Psychopharmacology. 2021;11:20451253211032053. doi:10.1177/20451253211032053. Go to original source... Go to PubMed...
    19. Serrano WC, Maldonado J. The Use of Physostigmine in the Diagnosis and Treatment of Anticholinergic Toxicity After Olanzapine Overdose: Literature Review and Case Report. Journal of the Academy of Consultation-Liaison Psychiatry. 2021;62(3):285-297. doi:10.1016/j.jaclp.2020.12.013. Go to original source... Go to PubMed...
    20. Hail S lynn, Obafemi A, Kleinschmidt KC. Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient. Clinical Toxicology (15563650). 2013;51(3):162-166. doi:10.3109/15563650.2013.773006. Go to original source... Go to PubMed...
    21. Hartvig P, Wiklund L, Lindström B. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anaesthesiologica Scandinavica. 1986;30:177-182. doi:10.1111/j.1399-6576.1986.tb02392.x. Go to original source... Go to PubMed...
    22. Arens AM, Shah K, Al-Abri S, et al. Safety and effectiveness of physostigmine: a 10-year retrospective review. Clinical Toxicology. 2018;56:101-107. doi:10.1080/15563650.2017.1342828. Go to original source... Go to PubMed...
    23. Rasimas JJ, Sachdeva KK, Donovan JW. Revival of an antidote: bedside experience with physostigmine. Toxicology Communications . 2018;2:85-101. doi:10.1080/24734306.2018.1535538. Go to original source...
    24. Temelor. Rozhodnutí o registraci. NR20711321.pdf. Státní ústav pro kontrolu léčiv. 2022. https://www.sukl.cz/modules/medication/detail.php?code=0259250&tab=texts.
    25. Mayerova M, Ustohal L, Jarkovsky J, Pivnicka J, Kasparek T, Ceskova E. Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations. Neuropsychiatric Disease & Treatment. 2018;14:1535-1543. doi:10.2147/NDT.S163839 Go to original source... Go to PubMed...
    26. Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 2014;4(3):e004216. Go to original source... Go to PubMed...
    27. Schoretsanitis G, Paulzen M, Unterecker S, et al. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians*. World Journal of Biological Psychiatry. 2018;19(3):162-174. doi:10.1080/15622975.2018.1439595. Go to original source... Go to PubMed...
    28. Detke HC et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 2010; 10:43. Go to original source... Go to PubMed...
    29. McDonnell DP et al (2010) Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry 10(1):45. Go to original source... Go to PubMed...
    30. Pollentier A, Vergaelen M, De Bleecker JL. Case report: Olanzapine post-injection delirium/sedation syndrome mimicking brainstem-thrombosis. Acta neurologica Belgica. 2021;121(5):1383-1384. doi:10.1007/s13760-021-01707-0. Go to original source... Go to PubMed...
    31. Fadhlina Misron SN, Othman Z, Misron LH. Anticholinergic delirium superimposed on severe cognitive deficit secondary to benzhexol and flupenthixol decanoate: A dilemma in management. Eastern Journal of Medicine. 2018;23(3):225-228. doi:10.5505/ejm.2018.41275. Go to original source...
    32. Filipe Almeida, Elisabete Albuquerque, Ilda Murta. Delirium Induced by Quetiapine and the Potential Role of Norquetiapine. Frontiers in Neuroscience. 2019;13. doi:10.3389/fnins.2019.00886. Go to original source... Go to PubMed...
    33. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2008;33(10):2303-2312. doi:10.1038/sj.npp.1301646. Go to original source... Go to PubMed...
    34. Ustohal L, Mayerova M, Valkova B, Sedlakova H, Kasparek T. Asymptomatic Elevation of Amylase and Lipase After Olanzapine Treatment. Journal of Clinical Psychopharmacology. 2016;36(2):181-183. doi:10.1097/JCP.0000000000000460. Go to original source... Go to PubMed...
    35. Singh GP, Kumar R, Bharti P. Tardive Dystonia with Olanzapine: A Rare Case Report. Indian Journal of Psychological Medicine. 2012;34(2):187-189. doi:10.4103/0253-7176.101795. Go to original source... Go to PubMed...
    36. Bracamonte JD, Underhill M, Sarmiento P. Acute pancreatitis associated with lisinopril and olanzapine. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2010;67(3):214-216. doi:10.2146/ajhp080519. Go to original source... Go to PubMed...
    37. Jaguga F. Clozapine-induced stuttering in the absence of known risk factors: a case report. Journal of Medical Case Reports. 2021;15(1):1-4. doi:10.1186/s13256-021-02803-8. Go to original source... Go to PubMed...
    38. Kacem M, Mami H, Sellami S, Moalla M, Ben Frej S, Bouzid R. Clozapine-induced parotitis: A case study. EUROPEAN PSYCHIATRY. 2021;64:S537. doi:10.1192/j.eurpsy.2021.1433. Go to original source...
    39. Asan O, Yaylaci ET, Göka E. A case of generalized edema associated with risperidone monotherapy. Klinik Psikiyatri Dergisi. 2019;22(4):501-503. doi:10.5505/kpd.2019.37029. Go to original source...
    40. Bhandari S, Baral MR, Zanatta JA. Possible Aripiprazole-Induced Hypothermia: An "Icy" Side Effect? Cureus. 2021;13(11):e19855. doi:10.7759/cureus.19855. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.